William Ragatz, MBA
Bill has more than 25 years of experience in the pharmaceutical and biotech industry. Most recently, Bill was Senior Vice President, Head of Commercial at Viela Bio where he built and led the global commercial organization and created the overall commercial vision for bringing pipeline assets to market. As an officer of the company, he was an integral team member for their IPO and the acquisition by Horizon Therapeutics. Prior to joining Viela, Bill was a Director for AstraZeneca where he led the worldwide commercial strategy for anifrolumab in systemic lupus erythematosus. Bill also spent 15 years at Boehringer-Ingelheim in roles of increasing responsibility, including leading the launch of respiratory, cardiovascular and oncology products. Bill started his pharmaceutical career at Merck and received his MBA from the Fuqua School of Business at Duke University. Bill brings to Sentrimed significant and broad commercial experience along with expertise in building strong organizations and successfully developing pipeline assets.
Dr. Arye Rosen, PhD
Dr. Rosen has published over 170 peer-reviewed papers, several books and book chapters, and an inventor on over 60 US patents that have been cited thousands of times (Google Scholar h-index 39 and i10-index 120). He is a member of the National Academy of Engineering, which is part of the National Academies of Sciences and Medicine. Dr. Rosen has been engaged in research at Jefferson Medical College in the Division of Cardiology for many years. He also held a position as Academy Professor of Biomedical and Electrical Engineering in the School of Biomedical Engineering, Science and Health Systems at Drexel University, where he served as a PI to perform NIH funded research. In 2003, Dr. Rosen cofounded the Medical Technology Center for Infants and Children at St. Peter’s University Hospital in New Brunswick, NJ. In 1988, he founded AMT Inc, (Advanced Medical Technologies) and has been serving as Vice President while engaging in research including a Phase I project funded by the Bill and Melinda Gates Foundation and other projects funded by NIH grants including SBIR and STTR mechanisms. More recently, Dr. Rosen has served as Associate Vice President for Biomedical Research Partnerships at Rowan University where he was responsible for fostering research initiatives. In particular, he worked to establish projects between Rowan’s medical school faculty and industry and government agencies. Dr. Rosen is especially adept at mentoring faculty working to develop and commercialize innovative medical technologies. This is where he met Dr. Goldberg and learned about work being pursued by Sentrimed. Dr. Rosen is eager to utilize his extensive experience to move Sentrimed into clinical trials and beyond.
Dr. Bradley S. Galer, MD
Dr. Galer has served as Zogenix Executive Vice President and Chief Medical Officer since December 2013, where he was involved in the licensing and global development of fenfluramine (FINTEPLA) for the treatment of rare devastating childhood-onset epilepsies, including Dravet syndrome and Lennox Gastaut syndrome. Prior to joining Zogenix, Dr. Galer served as President at Nuvo Research, a specialty pharmaceutical company with three commercialized topically delivered pain products. From 2000-2005 Dr. Galer was Endo Pharmaceuticals’ Senior Medical Officer and Group Vice President, Scientific Affairs. Prior to joining industry, Dr. Galer was on faculty at University of Washington and Albert Einstein College of Medicine. He has published over 200 articles in peer review journals and textbooks. Dr. Galer received his medical doctorate and a neurology residency from Albert Einstein in New York and two Fellowships, at Memorial Sloane-Kettering in New York and University of California San Francisco. Dr. Galer offers Sentrimed significant scientific, medical, and product development experience.
Dr. Jack Goldberg, MD
Jack Goldberg has over 40 years of experience and expertise in conducting clinical trials in oncology. In addition, he has basic research experience in hematopoietic stem cells and translational research in cancer. He has authored over 70 peer reviewed publications. He has been an active member of the Cancer and Acute Leukemia Group B and the Leukemia Intergroup. He has participated and directed clinical trials focused on leukemia and experience in bone marrow transplantation. He established community wide cancer research and received funding from the NIH for Community Clinical Oncology Program of New Jersey. He has also served from 1986 to 1989 as the Chairperson of the NCI Biology and Immunology Contracts Review Committee. He served the American Cancer Society Professor of Clinical Oncology from 1992 to 2002. In addition to Federal and NIH contributions, he established the Cooper Cancer Institute in Camden New Jersey in 1988, and the Abramson Comprehensive Cancer Center at Penn Presbyterian in 2002. He was certified by the American Board of Internal Medicine in 1976, American Subspecialty Board of Hematology in 1980, and American Subspecialty Board of Oncology in 1990. He serves on the board of the American Cancer Society Camden County. He will offer Sentrimed and our group of collaborators his years of experience in organizing and conducting clinical research in oncology.
Mr. Richard Kitei, JD
Richard Kitei earned his Bachelor’s degree from the University of Pennsylvania where he was involved in clinical research. He also has a Master’s degree from Georgetown University where he interned in the Intellectual Property division of the Department of Justice. He received his law degree from Temple University with a merit scholarship while working at 2 law offices and a technology transfer office. He has worked in technology development at the NIAID of the NIH where he worked with parasitic disease and immunogenetics intramural labs. He has also been involved as an employee, investor, and board member in various technology, health, and nanotech startup companies. He has been working with Rowan’s technology commercialization department since early 2018, and in the General Counsel office since early 2019. He has been licensed by PA and NJ and USPTO bars. Rick is well positioned to help Sentrimed achieve our scientific and business goals.
Mr. Mina Zion, JD
Mina Zion holds a JD from Rutgers Law School, and a BS in Chemical and Biological engineering from New York University. He serves as Director of Alliance Management of the Gene Therapy Program at the University of Pennsylvania where he works to build and facilitate collaborations for researchers in the healthcare space. Mina has over 10 years of experience across various industry and academic verticals, working to identify, evaluate and bridge research enterprises with industry collaborators. He recently served as Associate Director of Strategic Alliances and Corporate Collaborations in the Life Sciences at the University of Southern California. Mina was also the founding director of the Rowan University Office of Technology Commercialization, serving New Jersey’s second largest public healthcare university. At Rowan, he established and developed formal relationships with GlaxoSmithKline, Pfizer, Lockheed Martin, Stryker, Johnson and Johnson, and Bristol-Myers Squibb. Zion connects early stage innovators with established market leaders by regularly counseling early stage startup companies with a focus on corporate alliances and industry led mergers and acquisitions. Most notably, Mina out-licensed Rowan technology and shepherded the sale of startup licensee Bamboo Therapeutics to Pfizer for $200M ($50 + $150M), establishing Rowan OTC as a venerable tech transfer office. He also advised Rowan incubator tenant Web App Clouds, a Philadelphia-based startup company that recently earned a $100 million valuation. Prior to his career in academia, Mina worked with pre and post merger and integration teams at BASF Chemical Company and JPMorgan Chase.